Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging

Molecular Imaging and Biology

Volumn 16, Issue 3, 2014, Pages 372-382

  Tichauer, Kenneth M ^a   Deharvengt, Sophie J ^b   Samkoe, Kimberley S ^b,c   Gunn, Jason R ^c   Bosenberg, Marcus W ^d   Turk, Mary Jo ^b,e   Hasan, Tayyaba ^f   Stan, Radu V ^b   Pogue, Brian W ^b,c,e,f  

^a Illinois Institute of Technology   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH COLLEGE   (United States)

^d YALE UNIVERSITY   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Mouse model; PV1; Tracer kinetic modeling

Indexed keywords

CELL MEMBRANE PROTEIN; CLONE MECA32; FLUORESCENT DYE; MONOCLONAL ANTIBODY; PROTEIN PV1; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; DUAL TRACER FLUORESCENT IMAGING; ENDOTHELIAL MARKER CONCENTRATION IMAGING; FLUORESCENCE IMAGING; FLUORESCENT ANTIBODY TECHNIQUE; GENE OVEREXPRESSION; IMAGING SYSTEM; MELANOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; VASCULAR ENDOTHELIUM; ANIMAL; METABOLISM;

ANIMALS; FLUORESCENT DYES; MELANOMA; MICE; TUMOR MARKERS, BIOLOGICAL;

EID: 84902551091     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0692-1     Document Type: Article

References (36)

1. Nanda A, St Croix B (2004) Tumor endothelial markers: new targets for cancer therapy. Curr opin oncol 16:44-49 (Pubitemid 38703471)
2. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat med 10:145-147 (Pubitemid 38524883)
3. Fidler IJ (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat rev Cancer 3:453-458
4. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS nano 3:16-20
5. Wang D, Chen Y, Leigh SY et al (2012) Microscopic delineation of medulloblastoma margins in a transgenic mouse model using a topically applied VEGFR-1 probe. Transl oncol 5:408-414
6. Chernomordik V, Hassan M, Lee SB et al (2010) Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol imaging 9:192-200
7. Daghighian F, Pentlow KS, Larson SM et al (1993) Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur j nucl med 20:402-409 (Pubitemid 23204615)
8. Ferl GZ, Dumont RA, Hildebrandt IJ et al (2009) Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J nucl med : off publ, Soc Nucl Med 50:250-258
9. Zhang X, Xiong Z, Wu Y et al (2006) Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J nucl med : off publ, Soc Nucl Med 47:113-121 (Pubitemid 46768520)
10. Tafreshi NK, Silva A, Estrella VC et al (2013) In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharmaceutics 10(8):3175-3185
11. Tichauer KM, Samkoe KS, Sexton KJ et al (2012) In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Mol imaging biol : MIB : off publ Acad Mol Imaging 14:584-592
12. Liu JT, Helms MW, Mandella MJ et al (2009) Quantifying cell-surface biomarker expression in thick tissues with ratiometric three-dimensional microscopy. Biophys j 96:2405-2414
13. Pogue BW, Samkoe KS, Hextrum S et al (2010) Imaging targeted-agent binding in vivo with two probes. J biomed opt 15:030513
14. Tichauer KM, Samkoe KS, Klubben WS, Hasan T, Pogue BW (2012) Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. Phys med biol 57:6647-6659
15. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4:153-158
16. Logan J, Fowler JS, Volkow ND et al (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J cereb blood flow metab : off j Int Soc Cereb Blood Flow Metab 16:834-840
17. Stan RV, Roberts WG, Predescu D et al (1997) Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol biol cell 8:595-605 (Pubitemid 27176169)
18. Stan RV, Kubitza M, Palade GE (1999) PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc Natl Acad Sci U S A 96:13203-13207
19. Tkachenko E, Tse D, Sideleva O et al (2012) Caveolae, fenestrae and transendothelial channels retain PV1 on the surface of endothelial cells. PloS one 7:e32655
20. Stan RV, Tse D, Deharvengt SJ et al (2012) The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition. Dev cell 23:1203-1218
21. Tse D, Stan RV (2010) Morphological heterogeneity of endothelium. Semin thromb hemost 36:236-245
22. Stan RV (2007) Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. J cell mol med 11:621-643
23. Madden SL, Cook BP, Nacht M et al (2004) Vascular gene expression in nonneoplastic and malignant brain. Am j pathol 165:601-608 (Pubitemid 38971389)
24. Strickland LA, Jubb AM, Hongo JA et al (2005) Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J pathol 206:466-475 (Pubitemid 41025350)
25. Deharvengt SJ, Tse D, Sideleva O et al (2012) PV1 down-regulation via shRNA inhibits the growth of pancreatic adenocarcinoma xenografts. J cell mol med 16:2690-2700
26. Dankort D, Curley DP, Cartlidge RA et al (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552
27. Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J cereb blood flow metab : off j Int Soc Cereb Blood Flow Metab 27:1533-1539
28. Tichauer KM, Samkoe KS, Sexton KJ et al (2012) Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. J biomed opt 17:066001
29. Sexton K, Tichauer K, Samkoe KS, Gunn J, Hoopes PJ, Pogue BW (2013) Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PloS one 8:e60390
30. Kety SS (1951) The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol rev 3:1-41
31. de Lussanet QG, Langereis S, Beets-Tan RG et al (2005) Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 235:65-72 (Pubitemid 40432238)
32. Zhou M, Felder S, Rubinstein M et al (1993) Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. Biochemistry 32:8193-8198 (Pubitemid 23265809)
33. Valdes PA, Kim A, Leblond F et al (2011) Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery. J biomed opt 16:116007
34. Thurber GM, Dane Wittrup K (2012) A mechanistic compartmental model for total antibody uptake in tumors. J theor biol 314:57-68
35. Tolmachev V, Rosik D, Wallberg H et al (2010) Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 affibody molecule: aspect of the injected tracer amount. Eur j nucl med mol imaging 37:613-622
36. Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer res 48:7022-7032 (Pubitemid 19013976)